Assessing the Pharmacological Effects of a GPR65 Antagonist in a PDX Model of Clear Cell Renal Carcinoma

Time: 10:00 am
day: Day Two


  • Introduction to the pH sensing GPCR GPR65 as a genetically validated IO target
  • PDX model selection based on biological rationale, gene expression profiling and characterisation of the TME
  • Assessment of the effects of an orally administered GPR65 antagonist in a PDX model of clear cell renal carcinoma